Those who got in early on the cannabis boom, buying shares of some of these cannabis companies while many were still just penny stocks, made a lot of money.
I’m talking about companies such as: Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Aphria, Inc. (NYSE: APHA (TSX: APHA), Aurora Cannabis (NYSE: ACB) (TSX: ACB), Curaleaf (CSE: CURA) (OTCBB: CURLF), and Cronos Group (NASDAQ: CRON) (TSX: CRON).
While the cannabis market did eventually implode – as all overvalued markets inevitably do, a lot of the folks who made millions in the cannabis boom are now getting an early piece of the psychedelics market.
Some have suggested the two markets are very similar, although this isn’t entirely accurate.
Still, there are a handful of publicly-traded psychedelics companies that have been making early investors a boatload of cash.
Take Champignon Brands ((CSE: SHRM) OTCBB: SHRMF), for instance.
Three months ago, this thing was trading for $0.25 a share.
Since then, the stock has climbed as high as $1.74
That’s a nearly 600% gain in less than 3 months.
A $5,000 investment in Champignon back in March turned into more than $30,000 by May.
Not a bad way to make a buck!
Of course, this one has plenty of steam left in it, too, which is why I recently interviewed the CEO of Champignon, Dr. Roger Mcintyre.
You can watch the video here …
You can click here to learn more about some of the psychedelics stocks we’re investing in now.
